Literature DB >> 17294180

Amino acid 95 causes strong alteration of peptide position Pomega in HLA-B*41 variants.

Christina Bade-Doeding1, David S DeLuca, Axel Seltsam, Rainer Blasczyk, Britta Eiz-Vesper.   

Abstract

There have been several attempts over the years to identify positions in the peptide-binding region (PBR) of human leukocyte antigens (HLA) that influence the specificity of bound amino acids (AAs) at each position in the peptide. Originally, six pockets (A-F) were defined by calculating the surface area of the PBR on the crystal structure of HLA-A2 molecules. More recent crystallographic analyses of a variety of HLA alleles have led to broader pocket definitions. In this study, we examined the peptide-binding specificity of HLA-B*41 alleles and compared our results with the available pocket definitions. By generating recombinant HLA-B molecules and studying the eluted peptides by mass spectrometry and pool sequencing, we detected two different POmega peptide motifs within the B*41 group: Leu vs Val/Pro. Specificity was dependent on the presence of Leu (B*4102, B*4103, and B*4104) vs Trp (B*4101, B*4105, and B*4106) at AA position 95 in the HLA molecule, whose impact on POmega has been a subject of controversy in current pocket definitions. In contrast, the Arg97Ser mutation did not affect pocket F binding specificity in B*41 subtypes although residue 97 was previously identified as a modulator of peptide binding for several HLA class I alleles. According to most pocket definitions, this study shows that the Asn80Lys substitution in B*4105 impels the peptide's POmega anchor toward more promiscuity. Our sequencing results of peptides eluted from HLA-B*41 variants demonstrate the limitations of current pocket definitions and underline the need for an extended peptide motif database for improved understanding of peptide-major histocompatibility complex interactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294180     DOI: 10.1007/s00251-007-0197-7

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  24 in total

1.  A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity.

Authors:  Lars Kjer-Nielsen; Craig S Clements; Anthony W Purcell; Andrew G Brooks; James C Whisstock; Scott R Burrows; James McCluskey; Jamie Rossjohn
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

2.  Emerging principles for the recognition of peptide antigens by MHC class I molecules.

Authors:  M Matsumura; D H Fremont; P A Peterson; I A Wilson
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

3.  Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing.

Authors:  R Maier; K Falk; O Rötzschke; B Maier; V Gnau; S Stevanović; G Jung; H G Rammensee; A Meyerhans
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

4.  The Bw4/Bw6 difference between HLA-B*0802 and HLA-B*0801 changes the peptides endogenously bound and the stimulation of alloreactive T cells.

Authors:  K L Arnett; W Huang; N M Valiante; L D Barber; P Parham
Journal:  Immunogenetics       Date:  1998-06       Impact factor: 2.846

5.  Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity.

Authors:  L D Barber; L Percival; K L Arnett; J E Gumperz; L Chen; P Parham
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

Review 6.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

7.  Peptide motifs of HLA-B58, B60, B61, and B62 molecules.

Authors:  K Falk; O Rötzschke; M Takiguchi; V Gnau; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Structures of HLA-A*1101 complexed with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle, secondary anchor residue.

Authors:  Lenong Li; Marlene Bouvier
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

9.  Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes.

Authors:  L D Barber; B Gillece-Castro; L Percival; X Li; C Clayberger; P Parham
Journal:  Curr Biol       Date:  1995-02-01       Impact factor: 10.834

10.  Antagonist HIV-1 Gag peptides induce structural changes in HLA B8.

Authors:  S W Reid; S McAdam; K J Smith; P Klenerman; C A O'Callaghan; K Harlos; B K Jakobsen; A J McMichael; J I Bell; D I Stuart; E Y Jones
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

View more
  11 in total

1.  Position 45 influences the peptide binding motif of HLA-B*44:08.

Authors:  Soumya Badrinath; Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2011-10-19       Impact factor: 2.846

2.  Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Authors:  Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2012-06-16       Impact factor: 2.846

3.  The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family.

Authors:  Christina Bade-Döding; Alex Theodossis; Stephanie Gras; Lars Kjer-Nielsen; Britta Eiz-Vesper; Axel Seltsam; Trevor Huyton; Jamie Rossjohn; James McCluskey; Rainer Blasczyk
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

4.  Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.

Authors:  Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-09-01       Impact factor: 4.818

Review 5.  HLA-E: a novel player for histocompatibility.

Authors:  Thomas Kraemer; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-10-20       Impact factor: 4.818

6.  Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes.

Authors:  Maren Bieling; Sabine Tischer; Ulrich Kalinke; Rainer Blasczyk; Søren Buus; Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Oncotarget       Date:  2017-12-21

7.  The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity.

Authors:  Gwendolin S Simper; Lareen S Gräser; Alexander A Celik; Joachim Kuhn; Heike Kunze-Schumacher; Gia-Gia T Hò; Rainer Blasczyk; Andreas Pich; Christina Bade-Doeding
Journal:  Pharmaceutics       Date:  2019-10-15       Impact factor: 6.321

8.  HLA-B*1301 as a biomarker for genetic susceptibility to hypersensitivity dermatitis induced by trichloroethylene among workers in China.

Authors:  Haishan Li; Yufei Dai; Hanlin Huang; Laiyu Li; Shuguang Leng; Juan Cheng; Yong Niu; Huawei Duan; Qingjun Liu; Xing Zhang; Xianqing Huang; Jinxin Xie; Zhiming Feng; Juncai Wang; Jiaxi He; Yuxin Zheng
Journal:  Environ Health Perspect       Date:  2007-11       Impact factor: 9.031

9.  The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch.

Authors:  Alexander A Celik; Thomas Kraemer; Trevor Huyton; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2015-11-09       Impact factor: 2.846

10.  Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02.

Authors:  Gwendolin S Simper; Gia-Gia T Hò; Alexander A Celik; Trevor Huyton; Joachim Kuhn; Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Döding
Journal:  J Immunol Res       Date:  2018-09-13       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.